Young G P
Ann Emerg Med. 1984 Sep;13(9 Pt 1):712-22. doi: 10.1016/s0196-0644(84)80734-9.
Diltiazem, nifedipine, and verapamil inhibit calcium entry into cells via different mechanisms with different pharmacologies. They display different relative effects on different cardiovascular functions, a complex interplay of direct actions and adrenergic reflexes. Peripheral arterial vasorelaxation causes adrenergic reflex activity which opposes their direct negative chronotropic, dromotropic, inotropic, and hypotensive actions. Verapamil's most potent activity is electrophysiologic, and nifedipine's effects are hemodynamic; diltiazem acts like a less-potent combination of verapamil and nifedipine. All three drugs are efficacious in angina. These three drugs may not be interchangeable in all patients, but individualization of therapy is possible. Future indications for calcium channel blocker therapy may include hypertrophic cardiomyopathy, cerebral vasospasm, migraine headaches, pulmonary hypertension, asthma, esophageal spasm, intestinal ischemia, Raynaud's phenomenon, dysmenorrhea, and premature labor.
地尔硫䓬、硝苯地平和维拉帕米通过不同机制、不同药理作用抑制钙进入细胞。它们对不同心血管功能表现出不同的相对作用,是直接作用和肾上腺素能反射的复杂相互作用。外周动脉血管舒张会引起肾上腺素能反射活动,这与它们直接的负性变时、变传导、变力和降压作用相反。维拉帕米最显著的作用是电生理作用,硝苯地平的作用是血流动力学作用;地尔硫䓬的作用类似于维拉帕米和硝苯地平较弱作用的组合。这三种药物对心绞痛均有效。这三种药物在所有患者中可能并非都可互换,但治疗个体化是可行的。钙通道阻滞剂治疗未来的适应证可能包括肥厚型心肌病、脑血管痉挛、偏头痛、肺动脉高压、哮喘、食管痉挛、肠道缺血、雷诺现象、痛经和早产。